PAVmed Shares Are Trading Higher After the Company Announced It and Lucid Diagnostics Submitted Complete Clinical Evidence for Its Esoguard Esophageal DNA Test.

BenzingaNov 20 08:38 ET

Express News | PAVmed Shares Are Trading Higher After the Company Announced It and Lucid Diagnostics Submitted Complete Clinical Evidence for Its Esoguard Esophageal DNA Test

BenzingaNov 20 08:38 ET

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard Esophageal DNA Test

PR NewswireNov 20 07:56 ET

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

PR NewswireNov 18 08:15 ET

Maxim Group Maintains PAVmed(PAVM.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsNov 16 07:32 ET · Ratings

PAVmed Positioned for Growth Despite Q3 Revenue Miss: Buy Rating Affirmed by Anthony Vendetti

TipRanksNov 16 07:15 ET · Ratings